Trial Profile
A Randomized, Observer-Blind, Multicenter, Phase 2 Study to Assess the Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults of 65 Years of Age or Older
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs MT-2271 (Primary) ; GSK 2282512A
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 23 Oct 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 New trial record